Exact Sciences (EXAS) Tops Q1 EPS by 1c, Company Pleased with Launch Trajectory of Cologuard
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Exact Sciences Reports Strong Growth Trajectory for Cologuard™ in First-Quarter 2015
May 4, 2015 5:00 AM EDTMADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced its business and financial results for the quarter ending March 31, 2015, reporting that 11,000 Cologuard tests were completed and that the number of ordering physicians more than doubled, increasing from 4,100 at the end of 2014 to 8,300 in the first quarter of 2015.
We are pleased with the strong launch trajectory of Cologuard, said Kevin Conroy, Exact Sciences chairman and CEO. Demand among patients and physicians and acceptance among commercial insurers is accelerating.
The company expanded its team of sales professionals from 80 to 140 during... More
